Navigation Links
WaferGen to Present Data on SmartChip(TM) Real-Time PCR System at Cambridge Healthtech Institute's Quantitative PCR Conference
Date:3/10/2009

FREMONT, Calif., March 10 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art genetic analysis systems, today announced that Kumar Kastury, Ph.D., WaferGen's vice president of research and technical operations, will present data on the company's SmartChip(TM) Real-Time PCR System at the Cambridge Healthtech Institute's 5th Anniversary Quantitative PCR Conference. The conference will be held March 16-17 at the Hilton San Diego Resort in San Diego, CA.


    Details of the poster presentation are as follows:

    Title:    "SmartChip: A High-Throughput Real-Time PCR System that
              Combines Bio-marker Discovery and Validation into a Single
              Platform."

    Time:     From 5:45 p.m. (PDT) on Monday, March 16 until 4:15 p.m. (PDT)
              on Tuesday, March 17

    Summary:  An overview of the company's novel whole genome, high-throughput
              SmartChip Real-Time PCR System, as well as data highlighting the
              platform's analytical performance in evaluating differential
              gene expression between normal lung and tumor tissue samples.


WaferGen's SmartChip system is currently the focus of ongoing gene expression research collaborations with scientific teams at the University of Pittsburgh School of Medicine and the University of Texas, Southwestern. These programs are designed to leverage the SmartChip's innovative capabilities to identify and validate therapeutically-relevant gene expression biomarkers in areas including chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), lung cancer and wound healing. WaferGen believes this research may lead to the discovery of specific genes responsible for causing these diseases and conditions. In turn, this critical genetic information may ultimately provide physicians with new tools for determining accurate disease prognosis in patients, while also potentially providing drug developers with information necessary for the creation of targeted therapeutics.

About WaferGen

WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for genetic analysis for the life science and pharmaceutical industries. The company is actively developing its SmartChip(TM) product for the gene expression and genotyping markets. SmartChip is being developed as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform. This innovative system, combined with next-generation chemistry and optimized assays being developed by WaferGen, promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets. Based on collaborations established with leading research institutions, WaferGen believes that the SmartChip Real-Time PCR System is positioned as the platform of choice for biomarker discovery and validation. WaferGen currently markets its SmartSlide(TM) family of products to companies and organizations involved in stem cell and cell biology research. SmartSlide represents the first fluidics integrated micro-incubators enabling cell biology and stem cell research.

Forward-Looking Statements

This press release contains certain "forward-looking statements". Such statements include statements relating to the company's goals, plans and projections, anticipated results of research, performance, reliability and cost-effectiveness of the company's SmartChip and other systems, and other statements that are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words.

Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that: (i) the company may be unsuccessful in commercially developing its products or in achieving market acceptance of new and relatively unproven technologies; (ii) the company will need to raise additional capital to meet its business requirements in the future and the company may not be able to do so on reasonable terms or at all; (iii) the company's proprietary intellectual property rights may not adequately protect its products and technologies; and (iv) the company expects intense competition in its target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2007, and its subsequent Quarterly Reports on Form 10-Q filed with the SEC. Investors and security holders are urged to read this document free of charge on the SEC's web site at www.sec.gov. The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.


    Contact:

    Vida Communication (Media)             The Trout Group (Investors)
    Tim Brons                              Peter Rahmer
    415-675-7400                           646-378-2973
    tbrons@vidacommunication.com           San Francisco, CA

                                           or

                                           Christine Yang
                                           646-378-2929
                                           New York, NY


'/>"/>
SOURCE WaferGen Biosystems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Data on WaferGens SmartChip(TM) System Presented at 16th International Molecular Medicine Tri-Conference
2. Data on WaferGens SmartChip Real-Time PCR System(TM) to be Presented at 16th International Molecular Medicine Tri-Conference
3. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
4. WaferGen Announces Third Quarter 2008 Financial Results
5. WaferGen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
6. NIH Awards Approximately $3M Grant for Research Involving WaferGens SmartChip(TM) Real-Time PCR System at the University of Pittsburgh
7. WaferGen to Present at the Seventh Annual BIO Investor Forum
8. WaferGen Announces Second Quarter 2008 Financial Results
9. WaferGen to Present at the Ninth Annual Beyond Genome Conference
10. WaferGen Announces Signing of Two Private Placements
11. WaferGen to Present at the Rodman and Renshaw Fifth Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Sequenom, Inc. (NASDAQ: SQNM ), ... through the development of innovative products and services, announced ... United States denied its petition to review ... Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") are not ... the Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
Breaking Biology Technology:
(Date:6/22/2016)... On Monday, the Department of Homeland Security (DHS) issued ... the Biometric Exit Program. The Request for Information (RFI), ... that CBP intends to add biometrics to confirm when ... , in order to deter visa overstays, to ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
Breaking Biology News(10 mins):